Proteomics Managing Director Dr Richard Lipscombe said the study further validated PromarkerD.
“Excitingly, these latest findings further illustrate the benefits of the PromarkerD test by showing that we can also identify patients who are asymptomatic for diabetic kidney disease, and that canagliflozin improves their renal risk profile as well.“
The results will be presented at the Australasian Diabetes Congress in Brisbane which will take place from August 11 to 13, 2021.
Article: Proteomics International Laboratories (ASX:PIQ) shows diabetes drug improves PromarkerD risk scores
